Using monoamine oxidase inhibitors in patients with AD can reduce the level of ROS in neurons, avoid oxidative damage, and improve cognitive impairment.[30] The KEGG signal pathway includes neuroactive ligand-receptor interaction, cell senescence, cancer pathway, PI3K-AKT signal pathway, neurodegeneration, and HIF-1 signal pathway. Here, AKT1 is linked to Cognitive impairment.